Abstracts

Background: It is well-known that in patients with Alzheimer's disease (AD) and high education attainment, cognitive performance is typically better than expected based on the burden of brain neuropathology and neurodegeneration (Stern et al., 2018; doi: 10.1016/j.neuroimage.2018.05.033). This resilience of the cognitive status was attributed to a sort of cognitive reserve (CR) accumulated by persons with high education attainment, which predicts a life with engaging job, intellectual, and social demands (Arenaza-Urquijo et al. [...]

Background: To provide Person-Centered Care (PCC) for People with Dementia (PwD), patient’s stated preferences must be known. Data about stated care-preferences among PwD are limited. [...]

Background: Conventional blood sampling for the testing of Alzheimer's disease (AD) biomarkers depends on stringent, time-sensitive, and temperature-dependent protocols for processing, shipping, and storage. Dry plasma spots (DPS) present a simpler, more scalable alternative for the collection, storage, and transport of blood samples and may offer an alternative sampling when access to blood volume is limited. [...]

Alzheimer's disease (AD) is one of the most prevalent causes of dementia, while concomitant diseases such as cerebral amyloid angiopathy (CAA) has a substantial impact on clinical trajectories and therapy, i.e. risk factor for imaging abnormalities under anti-amyloid antibodies. [...]

There is substantial heterogeneity in clinical presentation of genetic Frontotemporal Dementia (FTD), even within the same family. This suggests that additional heritability may exist and contribute to this variable presentation. [...]

Aggregation of amyloid beta (Aβ) and tau proteins is a hallmark of Alzheimer's disease (AD) and tauopathies. In AD, extracellular deposition of Aβ peptide precedes tau aggregation and the onset of neuroinflammatory processes. [...]

Background: Understanding factors influencing Alzheimer's disease (AD) progression is crucial for optimising treatment timing and targets. A major genetic risk factor, the Apolipoprotein E ε4 allele (ApoE4), is associated with earlier tau pathology accumulation and spread at lower amyloid-beta (Aβ) levels (Steward, JAMA Neurol, 2023). [...]

Down syndrome (DS) is a genetic cause of Alzheimer's disease (AD), with virtually all individuals developing AD pathology by their fourth decade due to Amyloid Precursor Protein (APP) gene overexpression. In addition to amyloid beta (Aβ) plaques and hyperphosphorylated tau (p-Tau) aggregates, DS-associated AD (DSAD) often includes α-synuclein (αSyn) aggregates, contributing to Lewy body pathology (LBP). [...]

Background:High-resolution (7T) MRI facilitates in vivo imaging of fine anatomical structures selectively affected in Alzheimer's disease (AD), including medial temporal lobe subregions. However, 7T data is challenging to acquire and largely unavailable in clinical settings. [...]

The nucleus basalis of Meynert (NBM) is crucial for learning, attention, and memory. While its involvement in Alzheimer's disease (AD) has been widely reported, the role in frontotemporal dementia (FTD) remains unclear. [...]